BioPharma Drug Approval
Test detects 21 targets for 19 respiratory viruses in single tube, including COVID-19 and flu Assay result of Seegene's decades-long know-how, applies D...
April 07, 2022 | News
Pre-clinical trial results showed that CanSinoBIO's COVID-19 mRNA vaccine can induce high-titer neutralizing antibody levels against multiple SARS-CoV-2 va...
April 05, 2022 | News
On April 3, 2022, Ascletis' distributor, Zhejiang Int'l Medicine Co., Ltd. ("Zhejiang Int'l"), completed the first sale of Ascletis' ritonavir tablets...
April 05, 2022 | News
Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 9) released on March 15, 2022 by the National Health Commiss...
April 04, 2022 | News
CartiHeal Ltd, developer of implants for the treatment of cartilage and osteochondral defects in arthritic and non-arthritic knee-joints, today annou...
March 31, 2022 | News
Daewoong Pharmaceutical (CEO Sengho Jeon & Changjae Lee) recently announced that it has submitted the New Drug Application (NDA) for a n...
March 29, 2022 | News
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced tha...
March 22, 2022 | News
"The approval of CTA101 product IND is an important milestone for Bioheng in developing innovative immuno-cell therapies", said Xiaohong He, CEO of Bi...
March 18, 2022 | News
Under the terms of the agreement, Lynk Pharmaceuticals is responsible for the development of the product. Simcere will obtain the exclusive rights to marke...
March 18, 2022 | News
ATG-037 is the first orally-available, small molecule CD73 inhibitor to advance to clinical-stage by a Chinese company - The Phase I study will evaluate A...
February 07, 2022 | News
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative ph...
February 07, 2022 | News
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases,...
February 01, 2022 | News
BRUKINSA was granted its first breakthrough therapy designation in China with this application The application is supported by SEQUOIA trial results, whic...
January 31, 2022 | News
Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III Clinical Trial ReCOV induced high levels of neutralizing ...
January 18, 2022 | News
Most Read
Bio Jobs
News
Editor Picks